AcuCort joins Röda webben ahead of commercialization

AcuCort has joined the Röda webben services which is coordinated by the industry organization for pharmaceutical companies conducting research - LIF. The affiliation is a step towards the upcoming commercialization of the company's pharmaceutical product Zeqmelit®.

Within the pharmaceutical industry, there are elaborate complaint and recall procedures. The guidelines are collected on the so-called Röda webben and describe how complaints and withdrawals of medicines should be handled in Sweden. These guidelines constitute standards for the pharmaceutical industry with products on the Swedish market.

"The membership in Röda webben is an important part of the upcoming commercialization of our oral film Zeqmelit on the Swedish market. By joining the service, it is ensured that we follow the rules that surround complaints and withdrawals in Sweden", says AcuCort's CEO Jonas Jönmark.

For further information please contact:

Jonas Jönmark, vd, AcuCort AB

Telefon: 070 365 5400

Epost: [email protected]

About AcuCort AB (publ)
AcuCort has developed and commercializes Zeqmelit®, a new fast-dissolving oral film to be placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy and for the treatment of patients with covid-19 who need 2 supplemental oxygen therapy . Zeqmelit® is approved in Sweden, Denmark, Norway and Finland. All in all, it strengthens the company's assessment that the time until commercialization can be relatively short. AcuCort (short name: ACUC) is listed on the Spotlight Stock Market. Please visit www.acucort.se.